Aspirin is beneficial in hypertensive patients with chronic kidney disease: A post-hoc subgroup analysis of a randomized controlled trial

Journal of the American College of Cardiology

Volumn 56, Issue 12, 2010, Pages 956-965

  Jardine, Meg J ^a,b   Ninomiya, Toshiharu ^a   Perkovic, Vlado ^a   Cass, Alan ^a   Turnbull, Fiona ^a   Gallagher, Martin P ^a,b   Zoungas, Sophia ^a,c   Lambers Heerspink, Hiddo J ^a   Chalmers, John ^a   Zanchetti, Alberto ^d  

^a GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^b Department of Microbiology and Infectious Diseases   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

aspirin; bleeding; cardiovascular risk; chronic kidney disease; mortality; primary prevention; risk benefit analysis

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG FATALITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK FACTOR;

EID: 77956525281     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.02.068     Document Type: Article

References (43)

1. V. Perkovic, A. Cass, and A.A. Patel High prevalence of chronic kidney disease in Thailand Kidney Int 73 2008 473 479
2. S.J. Chadban, E.M. Briganti, and P.G. Kerr Prevalence of kidney damage in Australian adults: the AusDiab kidney study J Am Soc Nephrol 14 Suppl 2003 131 138
3. J. Coresh, B.C. Astor, T. Greene, G. Eknoyan, and A.S. Levey Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 41 2003 1 12
4. J. Coresh, E. Selvin, and L.A. Stevens Prevalence of chronic kidney disease in the United States JAMA 298 2007 2038 2047 (Pubitemid 350074801)
5. L.M. Ruilope, A. Salvetti, and K. Jamerson Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) study J Am Soc Nephrol 12 2001 218 225
6. A. Zanchetti, L. Hansson, and B.R. Dahlof Benefit and harm of low-dose aspirin in well-treated hypertensives at different baseline cardiovascular risk J Hypertens 20 2002 2301 2307
7. M.J. Sarnak, A.S. Levey, and A.C. Schoolwerth Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention Hypertension 42 2003 1050 1065
8. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
9. V. Perkovic, C. Verdon, and T. Ninomiya The relationship between proteinuria and coronary risk: a systematic review and meta-analysis PLoS Med 5 2008 e207
10. T. Ninomiya, V. Perkovic, and C. Verdon Proteinuria and stroke: a meta-analysis of cohort studies Am J Kidney Dis 53 2009 417 425
11. T. Ninomiya, V. Perkovic, and B.E. De Galan Albuminuria, kidney function and cardiovascular and renal outcomes in diabetes J Am Soc Nephrol 20 2009 1813 1821
12. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ 336 2008 645 651
13. V. Perkovic, T. Ninomiya, and H. Arima Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: data from the PROGRESS study J Am Soc Nephrol 18 2007 2766 2772
14. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch, and S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
15. C. Baigent, L. Blackwell, R. Collins Antithrombotic Trialists Collaboration Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials Lancet 373 2009 1849 1860
16. A.L. Weigert, and A.I. Schafer Uremic bleeding: pathogenesis and therapy Am J Med Sci 316 1998 94 104
17. M.W. Krause, M. Massing, and A. Kshirsagar Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease Renal Fail 26 2004 715 725
18. A.K. Berger, S. Duval, H.M. Krumholz, A.K. Berger, S. Duval, and H.M. Krumholz Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction J Am Coll Cardiol 42 2003 201 208
19. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial Lancet 351 1998 1755 1762 (Pubitemid 28269185)
20. A. Zanchetti, L. Hansson, and G. Leonetti Low-dose aspirin does not interfere with the blood pressure-lowering effects of antihypertensive therapy J Hypertens 20 2002 1015 1022
21. A. Levey, T. Greene, J. Kusek, G. Beck, and M.S. Group A simplified equation to predict glomerular filtration rate from serum creatinine (abstr) J Am Soc Nephrol 11 2000 155A
22. A.S. Levey, K.U. Eckardt, and Y. Tsukamoto Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) Kidney Int 67 2005 2089 2100
23. L. Hansson, and A. Zanchetti The Hypertension Optimal Treatment (HOT) studypatient characteristics: randomization, risk profiles, and early blood pressure results Blood Press 3 1994 322 327
24. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation C, and stratification Part 4. Definition and classification of stages of chronic kidney disease Am J Kidney Dis 39 Suppl 2002 46 75
25. A. Patel, S. MacMahon, and J. Chalmers Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial Lancet 370 2007 829 840
26. D.F. Easton, J. Peto, and A.G. Babiker Floating absolute risk: an alternative to relative risk in survival and case-control analysis avoiding an arbitrary reference group Stat Med 10 1991 1025 1035
27. M. Woodward Epidemiology: Study Design and Data Analysis 2nd edition 2004 Chapman and Hall/CRC Boca Raton, FL
28. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 2004 1296 1305
29. P.J.M. Best, S.R. Steinhubl, and P.B. Berger The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial Am Heart J 155 2008 687 693
30. B.K. Mahmoodi, R.T. Gansevoort, and N.J. Veeger Microalbuminuria and risk of venous thromboembolism JAMA 301 2009 1790 1797
31. K. Wattanakit, M. Cushman, and C. Stehman-Breen Chronic kidney disease increases risk for venous thromboembolism J Am Soc Nephrol 19 2008 135 140
32. D.P. Tveit, I.O. Hypolite, and P. Hshieh Chronic dialysis patients have high risk for pulmonary embolism Am J Kidney Dis 39 2002 1011 1017 (Pubitemid 34454219)
33. K.C. Abbott, D.F. Cruess, and L.Y. Agodoa Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States Am J Kidney Dis 43 2004 120 130
34. T. Eleftheriadis, G. Antoniadi, and V. Liakopoulos Propyl gallate-induced platelet aggregation in patients with end-stage renal disease: the influence of the haemodialysis procedure Nephrology 11 2006 3 8
35. D. Kaw, D. Malhotra, D. Kaw, and D. Malhotra Platelet dysfunction and end-stage renal disease Semin Dialysis 19 2006 317 322
36. G. Di Minno, A. Cerbone, and M. Usberti Platelet dysfunction in uremia II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen J Lab Clin Med 108 1986 246 252
37. V. Moal, P. Brunet, and L. Dou Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients Nephrol Dialysis Transplant 18 2003 1834 1841
38. J.S. Kaufman, T.Z. O'Connor, and J.H. Zhang Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis J Am Soc Nephrol 14 2003 2313 2321
39. T. Hasegawa, S.J. Elder, and J.L. Bragg-Gresham Consistent aspirin use associated with improved arteriovenous fistula survival among incident hemodialysis patients in the dialysis outcomes and practice patterns study Clin J Am Soc Nephrol 3 2008 1373 1378
40. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients BMJ 324 2002 71 86
41. B.S. Dixon, G.J. Beck, and M.A. Vazquez Effect of dipyridamole plus aspirin on hemodialysis graft patency N Engl J Med 360 2009 2191 2201
42. M.T.S. Keltai, M. Tonelli, and J.F.E. Mann Renal function and outcomes in acute coronary syndrome: impact of clopidogrel Eur J Cardiovasc Prevent Rehab 14 2007 312 318
43. A. Dasgupta, S.R. Steinhubl, and D.L. Bhatt Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial) Am J Cardiol 103 2009 1359 1363